following a full submission assessed under the end of life and orphan medicine process:
dacomitinib (Vizimpro®) is accepted for use within NHSScotland.
Indication under review: as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
In an open-label, randomised, phase III study, dacomitinib significantly improved progression-free survival compared with another EGFR tyrosine kinase inhibitor in adults with locally advanced or metastatic NSCLC with EGFR-activating mutations.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of dacomitinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Medicine details
- Medicine name:
- dacomitinib (Vizimpro)
- SMC ID:
- SMC2184
- Indication:
As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 September 2019